Company news
Neovasc Inc news in 2021
Neovasc Inc's news releases, calls and decks from 2021, newest first.
Neovasc to Participate in Sidoti December Virtual Microcap Conference
December 1, 2021
Neovasc Reducer(TM) System Receives National Reimbursement in France
November 30, 2021
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
November 24, 2021
The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System
November 24, 2021
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 9, 2021
Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
November 1, 2021
Neovasc Reducer(TM) Featured in Polish Heart Journal
October 21, 2021
Neovasc REDUCER-I Study Published in EuroIntervention Journal
September 28, 2021
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
September 23, 2021
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
September 16, 2021
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
August 30, 2021
Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
August 17, 2021
Neovasc Announces Second Quarter 2021 Financial Results
August 10, 2021
Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
July 27, 2021
Neovasc Announces New Appointments in Regulatory and Clinical Leadership
July 13, 2021
Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology
June 18, 2021
Neovasc Provides Corporate Update
June 10, 2021
Neovasc Reducer System Receives First National Reimbursement in Europe
June 7, 2021
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
June 3, 2021
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
May 25, 2021
Neovasc Provides Update on German Litigation
May 20, 2021
Neovasc to Sponsor Symposium on Reducer at EuroPCR
May 13, 2021
Neovasc Announces First Patient Enrollment in COSIMA Trial
May 10, 2021
Neovasc Announces First Quarter 2021 Financial Results
May 6, 2021
Neovasc Provides Reducer Reimbursement Progress Update
April 28, 2021
Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021
April 27, 2021
Neovasc Comments on EuroIntervention Article
April 19, 2021
Neovasc Provides Tiara TA Update
April 16, 2021
Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results
March 11, 2021
Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021
March 4, 2021
Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
March 3, 2021
Neovasc Comments on Clinical Cardiology Journal Publication
March 2, 2021
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
February 24, 2021
Neovasc to Participate in 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021
Neovasc Announces Closing of US$72 Million Registered Direct Offering of Common Shares Priced At-The-Market
February 12, 2021
Neovasc Announces US$72 Million Registered Direct Offering Priced At-The-Market
February 10, 2021
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
February 9, 2021
Neovasc Comments on Journal of the American Heart Association Publication
February 5, 2021
Neovasc Announces 2021 Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
February 2, 2021
American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
January 29, 2021
Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy
January 19, 2021
Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)
January 15, 2021
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
January 4, 2021